The company’s study of Thymitaq in patients with liver cancer failed to achieve its primary target of a survival benefit versus doxorubicin, an antibiotic often used in the treatment of liver carcinomas.
Eximias said additional data analysis would be conducted to better understand the results of the survival analysis and plan future activities.
Thymitaq is a drug that inhibits Thymidylate Synthase (TS) and disrupts DNA replication, thereby killing tumor cells. Thymitaq is one of the first molecularly targeted products, using a high-resolution crystal structure of the TS target and molecular modeling techniques to design a product that could overcome some of the known resistance mechanisms of classical antifolates.